THE DEAL, AT A GLANCE
1/4 reviewedNeurosterix
What it doesNeurosterix designs targeted treatments for mental health conditions, including psychosis, mood disorders, and anxiety.Source-grounded · automated review · Explore ↗
Checked 2026-11-13 · Review due 2026-11-20
Read supporting source ↗Harnessing the power of allosteric…
Who is involvedBacked by Perceptive Life Sciences Fund, Acorn Bioventures, Addex TherapeuticsFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗What happenedNeurosterix raised $105M Series B, announced 2026-11-11From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Why it mattersNeurosterix closed a $105 Million Series B financing as its lead program NTX-253 is ready for Phase 2 clinical development.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Neurosterix · Financing Record
Explore source-linked visual explanations for Neurosterix. Unsupported claims are withheld while source review continues.
Record 15851 · Recorded date: 2026-11-11
Explore company records →